Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

Launched by SUGEN · Aug 30, 2001

Keywords

ClinConnect Summary

Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• You may be eligible for this study if you:
• • Are at least 18 years old.
• • Are HIV-positive.
• • Have KS with at least 5 skin lesions.
• • Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
• • Agree to use effective methods of birth control during the study.
• • Exclusion Criteria
• You will not be eligible for this study if you:
• • Have had surgery within 4 weeks of study entry.
• • Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
• • Have pulmonary KS (KS in your lungs).
• • Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
• • Are allergic to Cremophor.
• • Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
• • Are pregnant.